Avellino Labs
Professor Kinoshita graduated from Osaka University Medical School in 1974 and has served as the Professor and Chairman of Ophthalmology at Kyoto Prefectural University of Medicine since 1992. In the early 1980s, he collaborated with Dr. Richard A. Toft at The Schepens Eye Research Institute in Boston and completed a cornea fellowship at Harvard Medical School. He is known in the global ophthalmic community for his groundbreaking and innovative research concerning the cornea. Professor Kinoshita will help guide the company’s research efforts to develop genetics-based personalized medicine solutions to diagnose and treat corneal dystrophies, a leading cause of visual impairment that affects more than 900 million people in the developed world and accounts for roughly half of the keratoplasty, or corneal transplant, surgeries performed today.
This person is not in the org chart
This person is not in any offices
Avellino Labs
Avellino Labs is a global leader in gene therapy and molecular diagnostics, and the pioneer in personalized medicine for eye care. Avellino Labs is pioneering CRISPR gene editing to manage and potentially cure inherited diseases. Avellino Labs continues to expand its diagnostics capabilities, building on the success of the world's first DNA test to confirm the presence of genetic indicators that are positively associated with corneal dystrophies, providing life-changing information for patient treatment decisions and follow up care. Avellino Labs is headquartered in Silicon Valley, California, with operations in Korea, Japan, China and the UK.